Status:
UNKNOWN
Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing
Lead Sponsor:
Far Eastern Memorial Hospital
Conditions:
Overactive Bladder Syndrome
Eligibility:
FEMALE
20+ years
Phase:
PHASE4
Brief Summary
The aim of this study is to elucidate whether night-time dosing of mirebegron can improve nocturia, compared with daytime dosing of mirabegron.
Detailed Description
Background/Purpose: Women with overactive bladder syndrome (OAB) may have symptoms of nocturia, in addition to urgency and frequency. Women with nocturia are prone to suffer from a fall and fracture. ...
Eligibility Criteria
Inclusion
- OAB symptoms for at least one month
- \>20 years
Exclusion
- Allergy to mirabegron, urinary tract infections, unstable hypertension
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03251300
Start Date
August 1 2017
End Date
December 31 2024
Last Update
March 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Far Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan, 22050